Activation of the ALK-5 pathway is not per se sufficient for the antiproliferative effect of TGF-β1 on renal tubule epithelial cells

Cellular Physiology and Biochemistry

Volumn 37, Issue 4, 2015, Pages 1231-1239

  García Sánchez, Omar ^c   Sancho Martínez, Sandra M ^b,c,d   López Novoa, José Miguel ^b,c,d   López Hernández, Francisco J ^a,b,c,d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d Section of Nephrology   (Spain)

Author keywords

ALK 5; Cell proliferation; Renal tubular epithelial cells; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIVIN LIKE KINASE RECEPTOR 5; MEMBRANE RECEPTOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE ASSAY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SIGNALING ASSAY; CELL VIABILITY; CELL VIABILITY ASSAY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KIDNEY TUBULE EPITHELIUM; MDCK CELL LINE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DOG; DRUG EFFECTS; EPITHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; KIDNEY TUBULE; METABOLISM;

ANIMALS; BENZAMIDES; CELL LINE; CELL PROLIFERATION; DIOXOLES; DNA FRAGMENTATION; DOGS; EPITHELIAL CELLS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; KIDNEY TUBULES; MADIN DARBY CANINE KIDNEY CELLS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84943278217     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430246     Document Type: Article

References (31)

1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010:375:1296-1309.
2. Lopez-Novoa JM, Rodriguez-Peña AB, Ortiz A, Martinez-Salgado C, Lopez-Hernandez FJ. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications. J Trans Med 2001;9:13.
3. Fogo AB.: Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007;22:2011-2022.
4. Garcia-Sachez O, Lopez-Hernandez FJ, Lopez-Novoa JM. An integrative view on the role of TGF-β in the progressive tubular deletion associated with chronic kidney disease. Kidney Int 2010;77:950-955.
5. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-296.
6. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and endstage renal disease (ESRD) therapies-An international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999;14:31-41.
7. Docherty NG, Morales AI, Lopez Novoa JM, Pérez Barriocanal F. La transicion de células epiteliales a miofibroblastos.Mecanismos involucrados y su posible relacion con la fibrosis renal. Nefrologia 2007;27:681-688.
8. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitialfibrosis. Am J Pathol 2001;159:1465-1475.
9. Ishibe S, Cantley LG. Epithelial-mesenchymal-epithelial cycling in kidney repair. Curr Opin Nephrol Hypertens 2008;17:379-385.
10. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535-543.
11. Yang L, Humphreys BD, Bonventre JV. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol 2011;174:149-155.
12. Lan A, Qi Y, Du J. Akt2 mediates TGF-β1-induced epithelial to mesenchymal transition by deactivating GSK3β/snail signaling pathway in renal tubular epithelial cells. Cell Physiol Biochem 2014;34:368-382.
13. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-791.
14. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
15. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3:807-820.
16. Li Y, Tan X, Dai C, Stolz DB, Wang D, Liu Y. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J Am Soc Nephrol 2009;20:1907-1918.
17. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005;65:599-608.
18. Bonventre JV. Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation. Contrib Nephrol 2007;156:39-46.
19. Gewin L, Vadivelu S, Neelisetty S, Srichai MB, Paueksakon P, Pozzi A, Harris RC, Zent R. Deleting the TGF-β receptor attenuates acute proximal tubule injury. J Am Soc Nephrol 2012;23:2001-2011.
20. Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Peña AB, Lopez-Hernandez FJ. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 2010;128:61-81.
21. Docherty NG, O'Sullivan OE, Healy DA, Murphy M, O'neill AJ, Fitzpatrick JM, Watson RW. TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol 2006;290:F1202-1212.
22. Wen X, Murugan R, Peng Z, Kellum JA. Pathophysiology of acute kidney injury: a new perspective. Contrib Nephrol 2010;165:39-45.
23. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W Jr, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012;18:396-404.
24. Meng XM, Chung AC, Lan HY. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) 2013;124:243-254.
25. Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int 2000;57:937-948.
26. Matsumoto K, Nakamura T. Renotropic role and therapeutic potential of HGF in the kidney. Nephrol Dial Transplant 2002;17:59-61.
27. Carrero JJ, Park SH, Axelsson J, Lindholm B, Stenvinkel P. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial 2009;22:381-386.
28. Lin S, Yu L, Yang J, Liu Z, Karia B, Bishop AJ, Jackson J, Lozano G, Copland JA, Mu X, Sun B, Sun LZ. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and-independent signaling activity of transforming growth factor-β (TGF-β). J Biol Chem 2011;286:44023-44034.
29. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 2003;113:301-314.
30. Dupont S, Zacchigna L, Adorno M, Soligo S, Volpin D, Piccolo S, Cordenonsi M. Convergence of p53 and TGF-beta signaling networks. Cancer Lett 2004;213:129-138.
31. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, Soligo S, Dupont S, Piccolo S. Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science 2007;315:840-843.